Add news
Нами Накагава — Kimi Wa Kirameki/Ты - Сияние! (feat. Ichigo Tanuki)
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020November 2020December 2020January 2021February 2021March 2021April 2021May 2021June 2021July 2021
News Every Day |

Daiichi Sankyo to launch important Covid-19 clinical trial: mRNA, Covid-19, and cancer

Daiichi Sankyo to launch important Covid-19 trial: mRNA, Covid-19, and cancer

Kanako Mita and Sawako Utsumi

Modern Tokyo Times

The Japanese pharmaceutical sector is slow off the mark compared with several nations where mRNA coronavirus vaccines and non-mRNA vaccines are already being used. However, the Japanese companies of AnGes, Daiichi Sankyo, KM Biologics, and Shionogi are now at different stages concerning their own vaccine program.

In Japan, the two mRNA vaccines being used are from Moderna (US) and the joint venture of Pfizer (US) and BioNTech (Germany). Hence, Japan relies on other international companies to supply vaccines to stem the coronavirus crisis. Therefore, it is welcomed that four Japanese pharmaceutical companies are focused on respective clinical trials.

NHK reports, “Japanese pharmaceutical company Daiichi Sankyo is preparing to launch a large-scale clinical trial on its experimental coronavirus mRNA vaccine as early as this year.”

Daiichi Sankyo’s clinical trial concerns several thousand individuals. However, unlike usual clinical trials that utilize the placebo angle, it is believed that a noninferiority test to monitor the number of antibodies produced will be checked against current vaccines. Therefore, with international vaccines already being used in Japan, this will bypass the unethical angle of using a placebo when vaccines already exist.

Lee Jay Walker says, “If the clinical trial is successful, then Daiichi Sankyo hopes to provide an mRNA coronavirus vaccine next year once approved in Japan. Daiichi Sankyo also hopes to use mRNA vaccines for the treatment of cancer and gene therapy.”

Indeed, mRNA angles concerning cancer treatment could unleash major developments. The National Geographic reports, “Back when people first heard about Pfizer-BioNTech and Moderna’s COVID-19 vaccines, the mRNA technology behind them sounded like the stuff of science fiction. But while the mRNA approach seems revolutionary, long before anyone had heard of COVID-19, researchers had been developing mRNA vaccines to fight cancer, autoimmune diseases such as multiple sclerosis, and to protect against other infectious diseases, such as the respiratory syncytial virus. “It’s not a new idea: What COVID has shown us is that mRNA vaccines can be an efficacious and safe technology for millions of people,” says Daniel Anderson, a leader in the field of nanotherapeutics and biomaterials at the Massachusetts Institute of Technology and a member of the Koch Institute for Integrative Cancer Research.”

It is hoped that Japanese coronavirus vaccines will be available from next year. Similarly, that Japanese companies will focus on mRNA angles concerning cancer treatment, gene therapy, and other important areas.


Modern Tokyo News is part of the Modern Tokyo Times group

DONATIONS to SUPPORT MODERN TOKYO TIMES – please pay PayPal and DONATE to Modern Tokyo Times – International News and Japan News Modern Tokyo Times is now on PINTEREST – Sawako Utsumi personal website and Modern Tokyo Times artist Modern Tokyo News – Tokyo News and International News

PLEASE JOIN ON TWITTER Modern Tokyo Times Facebook

The post Daiichi Sankyo to launch important Covid-19 clinical trial: mRNA, Covid-19, and cancer first appeared on Modern Tokyo Times.

Read also

Biden's belief that Putin is conspiring with China to take down democracy betrays his complete ignorance of Russia's own politics

Ryan Giggs due to appear in court today after ‘drunkenly headbutting ex-girlfriend in 3 years of abuse’

First installment of American Rescue Plan funding brings $29.4 million to Vermont

News, articles, comments, with a minute-by-minute update, now on — latest news 24/7. You can add your news instantly now — here
News Every Day

Cheese Market Revenue Growth Defined by Heightened Product Innovation